Evidence map›Paper›PMID 25136665›Full record

ArticleTheScientificWorldJournal2014

Kinetics of mushroom tyrosinase and melanogenesis inhibition by N-acetyl-pentapeptides.

Ching-Yi Lien, Ching-Yu Chen, Shih-Ting Lai, Chin-Feng Chan

Open access · goldAbstract read
In one paragraph

Article in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Kinetics of Tyrosinase Inhibitory Activity UsingBioMed research international · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ching-Yi LienDepartment of Chemistry, National Chiayi University, Chiayi 60004, Taiwan.
Ching-Yu ChenDepartment of Applied Cosmetology, Hungkuang University, No. 1018, Sector 6, Taiwan Boulevard, Shalu District, Taichung 43302, Taiwan.
Shih-Ting LaiDepartment of Applied Cosmetology, Hungkuang University, No. 1018, Sector 6, Taiwan Boulevard, Shalu District, Taichung 43302, Taiwan.
Chin-Feng ChanDepartment of Applied Cosmetology, Hungkuang University, No. 1018, Sector 6, Taiwan Boulevard, Shalu District, Taichung 43302, Taiwan.ORCID 0000-0003-1681-8651
Hungkuang University · TWNational Chiayi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the kinetics of 4N-acetyl-pentapeptides, Ac-P1, Ac-P2, Ac-P3, and Ac-P4, regarding inhibition of mushroom tyrosinase activity. The peptides sequences of Ac-P1, Ac-P2, Ac-P3, and Ac-P4 were Ac-RSRFK, Ac-KSRFR, Ac-KSSFR, and Ac-RSRFS, respectively. The 4N-acetyl-pentapeptides were able to reduce the oxidation of l-DOPA by tyrosinase in a dose-dependent manner. Of the 4N-acetyl-pentapeptides, only Ac-P4 exhibited lag time (80 s) at a concentration of 0.5 mg/mL. The tyrosinase inhibitory effects of Ac-P4 (IC50 0.29 mg/mL) were more effective than those of Ac-P1, Ac-P2, and Ac-P3, in which IC50s were 0.75 mg/mL, 0.78 mg/mL, and 0.81 mg/mL, respectively. Kinetic analysis demonstrated that all 4N-acetyl-pentapeptides were mixed-type tyrosinase inhibitors. Furthermore, 0.1 mg/mL of Ac-P4 exhibited significant melanogenesis inhibition on B16F10 melanoma cells and was more effective than kojic acid. The melanogenesis inhibition of Ac-P4 was dose-dependent and did not induce any cytotoxicity on B16F10 melanoma cells.

Indexed as

AgaricalesCell Line, TumorCell SurvivalEnzyme ActivationHumansKineticsMelanomaMonophenol MonooxygenaseOligopeptidesMonophenol MonooxygenaseOligopeptides

Identifiers

PMID25136665
PMCPMC4130364
OpenAlexW2095744862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.